91 related articles for article (PubMed ID: 28069100)
1. Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
Monogue ML; Tanner LK; Brecher SM; Aslanzadeh J; Nicolau DP
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):379-380. PubMed ID: 28069100
[No Abstract] [Full Text] [Related]
2. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
3. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
4. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
6.
Stainton SM; Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
[TBL] [Abstract][Full Text] [Related]
7. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
[TBL] [Abstract][Full Text] [Related]
8. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
[TBL] [Abstract][Full Text] [Related]
9. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
10. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
Kurpiel PM; Hanson ND
J Antimicrob Chemother; 2012 Feb; 67(2):339-45. PubMed ID: 22117029
[TBL] [Abstract][Full Text] [Related]
11. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
12. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
London N; Thomson CJ; Amyes SG; Stobberingh E
FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
[TBL] [Abstract][Full Text] [Related]
13. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
Rodríguez-Villodres Á; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061749
[No Abstract] [Full Text] [Related]
14. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
[TBL] [Abstract][Full Text] [Related]
16. Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
Pinet E; Franceschi C; Davin-Regli A; Zambardi G; Pagès JM
J Med Microbiol; 2015 Nov; 64(11):1305-1314. PubMed ID: 26242994
[TBL] [Abstract][Full Text] [Related]
17. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Sader HS; Hsiung A; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.
Stainton SM; Thabit AK; Kuti JL; Aslanzadeh J; Nicolau DP
Clin Microbiol Infect; 2017 Aug; 23(8):581-582. PubMed ID: 28254605
[No Abstract] [Full Text] [Related]
19. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
